SOT/EUROTOX Debate: Biomarkers From Blood and Urine Will Replace Traditional Histopathological Evaluation to Determine Adverse Responses

A generic operational strategy to qualify translational safety biomarkers

(2011) Katja Matheis et al.   DRUG DISCOVERY TODAY

Certification and maintenance of certification: updates from the American Board of Pathology

(2011) Betsy D. Bennett et al.   HUMAN PATHOLOGY

Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses

(2011) John P. A. Ioannidis   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recommendations for the Evaluation of Pathology Data in Nonclinical Safety Biomarker Qualification Studies

(2011) John E. Burkhardt et al.   TOXICOLOGIC PATHOLOGY

A roadmap for biomarker qualification

(2010) David G Warnock et al.   NATURE BIOTECHNOLOGY

Next-generation biomarkers for detecting kidney toxicity

(2010) Joseph V Bonventre et al.   NATURE BIOTECHNOLOGY

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

(2010) Frank Dieterle et al.   NATURE BIOTECHNOLOGY

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

(2010) Vishal S Vaidya et al.   NATURE BIOTECHNOLOGY

Spending on new drug development

(2009) Christopher Paul Adams et al.   HEALTH ECONOMICS

Creatinine as the gold standard for kidney injury biomarker studies?

(2009) S. S. Waikar et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

RNA expression analysis from formalin fixed paraffin embedded tissues

(2008) Susan M. Farragher et al.   HISTOCHEMISTRY AND CELL BIOLOGY